Eloxx Pharmaceuticals' stock price is likely to go up in the short term due to the positive news of ELX-02 advancing to a pivotal trial for the treatment of Alport Syndrome. This advancement indicates that the drug candidate has shown promising results in the Phase 2 study, which could potentially lead to regulatory approval and commercialization, thus benefiting the company's financial performance and shareholder value.